膀胱癌和肾癌治疗和研究的目标是使患者受益-泌尿外科杂志(电子版)

• 主编手记 •

膀胱癌和肾癌治疗和研究的目标是使患者受益

许清泉,

收稿日期：2023-06-29 接受日期：2023-06-29 出版日期：2023-06-29 发布日期：2023-06-29

通讯作者：

作者简介： 许清泉,男,北京大学人民医院泌尿外科，北京 100034,主任医师 .

基金资助：，项目负责人：

中图分类号：R737.25

文献标识码：A

文章编号：1674-7410(2023)02-0001-02

DOI：10.20020/j.CNKI.1674-7410.2023.02.01

关键词： 膀胱癌, 肾癌, 淋巴结清扫, 根治性切除术, 免疫治疗,

PDF

摘要/Abstract
图/表(结果)0
参考文献
引⽤本⽂
相关文章0
引言
材料方法
讨论
文章快阅
延伸阅读

（详情见文章内容）

暂无相关信息！

[1] 邱海波，曹素梅，徐瑞华，基于2020年全球流行病学数据分析中国癌症发病率、死亡率和负担的时间趋势及与美国和英国数据的比较[J].癌症，2022,41(4):165-177.

[2] JUBBER I, ONG S,BUKAVINA L, et al. Epidemiology of Bladder Cancer in 2023:A Systematic Review of Risk Factors [J]. European Urology, 2023:S0302283823027070.

[3] HUANG J,LEUNG DK,CHAN EO,et al. A Global Trend Analysis of Kidney Cancer Incidence and Mortality and Their Associations with Smoking, Alcohol Consumption,and Metabolic Syndrome [J]. Eur Urol Focus, 2022,8(1):200-209.

[4] LIU Z,YANG Z,LI J, et al. The effectiveness of partial versus radical nephrectomy for pT3aNOM0 renal cell carcinoma: A propensity score analysis [J]. Asian J Surg,2023: S1015-9584(23)00571-7.

[5] MIR MC,DERWEESH I,PORPIGLIA F,et al. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies [J]. Eur Urol, 2017,71(4):606-617.

[6] SHVERO A,NATIV O,ABU-GHANEM Y,et al.Oncologic Outcomes of Partial Nephrectomy for Stage T3a Renal Cell Cancer [J]. Clin Genitourin Cancer,2018,16(3): e613-e617

[7] CHOUEIRI TK,POWLES T,ALBIGES L, et al.Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma [J]. N Engl J Med,2023,388(19): 1767-1778.

[8] ALDIN A, BESIROGLU B,ADAMS A,et al. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis [J]. Cochrane Database Syst Rev, 2023,5(5): CD013798.

[9] LALANI AA,KAPOOR A, BASAPPA NS,et al. Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statement [J]. Can Urol Assoc J,2023,17(5): E154-E163.

[10] BEDKE J,ALBIGES L, CAPITANIO U,et al. The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma [J]. Eur Urol,2023,83(1):10-14.

[11] ZLOTTA AR,BALLAS LK, NIEMIERKO A,et al. Radical cystectomy versus trimodality therapy for muscle- invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis [J]. Lancet Oncol,2023:S1470-2045(23)00170-5.

[12] BAJORIN DF,WITJES JA,GSCHWEND JE,et al. Adjuvant Nivolumab versus Placebo in Muscle- Invasive Urothelial Carcinoma [J]. New Engl J Med, 2021, 384(22): 2102-2114

[13] POWLES T,PARK SH,CASERTA C,et al. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up [J]. J Clin Oncol,2023: JCO2201792.

许清泉.膀胱癌和肾癌治疗和研究的目标是使患者受益[J]. 泌尿外科杂志（电子版）,2023,15(2):1-2. DOI:10.20020/j.CNKI.1674-7410.2023.02.01

暂无相关信息！

作者相关文章

许清泉